Related Experiment Videos
Neuroprotective effects of pramipexole in young and aged MPTP-treated mice
D W Anderson1, T Neavin, J A Smith
1Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, JAH 521, Philadelphia, PA 19107, USA.
Abstract:
This study examined the effect of pramipexole (PPX), a selective dopamine (DA) D(3)/D(2) agonist, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage to the nigrostriatal dopamine system in young (8-week-old) and aged (12-month-old) mice. Co-administration of PPX and MPTP to young or aged mice, followed by 2 or 14 days of additional PPX treatment, significantly attenuated MPTP-induced striatal DA loss. Pramipexole treatment also significantly attenuated the loss of tyrosine hydroxylase immunoreactive neurons (TH-IR) within the substantia nigra pars compacta (SNc) in both young and aged animals. Effects of PPX administration on dopaminergic cell survival were confirmed in Nissl-stained sections and by quantitation of retrogradely labeled Fluorogold-positive SNc neurons. Protective effects of PPX on striatal DA levels and SNc DA neuron survival were similar in young and aged animals, although the magnitude of these effects was significantly less in aged animals. These findings support the early initiation of PPX therapy in Parkinson's disease patients.
Insights
Pramipexole (PPX) protects against dopamine system damage in mice, showing potential for Parkinson's disease treatment. Early PPX therapy may benefit patients by preserving dopamine levels and neuron survival.
Area of Science:
- Neuroscience
- Pharmacology
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to model PD-like pathology.
- Dopamine (DA) agonists, such as pramipexole (PPX), are used in PD treatment.
Purpose of the Study:
- To investigate the neuroprotective effects of pramipexole (PPX) against MPTP-induced dopaminergic neurodegeneration.
- To compare the efficacy of PPX in young and aged animal models.
Main Methods:
- MPTP was administered to young and aged mice to induce nigrostriatal damage.
- Pramipexole (PPX) was co-administered with MPTP, followed by additional PPX treatment.
- Striatal dopamine levels, tyrosine hydroxylase-immunoreactive (TH-IR) neurons, and dopaminergic cell survival were quantified.
Main Results:
- PPX significantly attenuated MPTP-induced striatal DA loss and loss of TH-IR neurons in the substantia nigra pars compacta (SNc).
- Neuroprotective effects of PPX were observed in both young and aged mice.
- The magnitude of PPX's protective effects was reduced in aged animals compared to young animals.
Conclusions:
- Pramipexole demonstrates significant neuroprotective effects against MPTP-induced dopaminergic neurodegeneration.
- These findings suggest that early initiation of pramipexole therapy may be beneficial for Parkinson's disease patients.
- Age influences the magnitude of pramipexole's neuroprotective efficacy.